320 related articles for article (PubMed ID: 8586461)
21. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
22. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
Reardon DA; Zalutsky MR; Bigner DD
Expert Rev Anticancer Ther; 2007 May; 7(5):675-87. PubMed ID: 17492931
[TBL] [Abstract][Full Text] [Related]
23. Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination.
Yu JS; Luptrawan A; Black KL; Liu G
Clin Neurosurg; 2006; 53():345-51. PubMed ID: 17380773
[TBL] [Abstract][Full Text] [Related]
24. Antibodies in the therapy of colon cancer.
Welt S; Ritter G
Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
[TBL] [Abstract][Full Text] [Related]
25. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.
Mitra S; Li G; Harsh GR
Neurosurg Clin N Am; 2010 Jan; 21(1):67-76. PubMed ID: 19944967
[TBL] [Abstract][Full Text] [Related]
26. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
27. Tumor markers of the central nervous system: biological basis and clinical relevance.
Birkmayer GD
Cancer Detect Prev; 1983; 6(1-2):317-24. PubMed ID: 6883389
[TBL] [Abstract][Full Text] [Related]
28. T cell adoptive immunotherapy of newly diagnosed gliomas.
Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
[TBL] [Abstract][Full Text] [Related]
29. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.
Bourdon MA; Wikstrand CJ; Furthmayr H; Matthews TJ; Bigner DD
Cancer Res; 1983 Jun; 43(6):2796-805. PubMed ID: 6342760
[TBL] [Abstract][Full Text] [Related]
30. Patterns of antigenic expression of human glioma cells.
McKeever PE; Davenport RD; Shakui P
Crit Rev Neurobiol; 1991; 6(2):119-47. PubMed ID: 1934088
[TBL] [Abstract][Full Text] [Related]
31. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.
Mizoguchi M; Betensky RA; Batchelor TT; Bernay DC; Louis DN; Nutt CL
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1181-8. PubMed ID: 17146292
[TBL] [Abstract][Full Text] [Related]
32. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
[TBL] [Abstract][Full Text] [Related]
34. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.
Modak S; Gerald W; Cheung NK
Med Pediatr Oncol; 2002 Dec; 39(6):547-51. PubMed ID: 12376975
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
[TBL] [Abstract][Full Text] [Related]
36. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
Nicholas MK; Lukas RV; Jafri NF; Faoro L; Salgia R
Clin Cancer Res; 2006 Dec; 12(24):7261-70. PubMed ID: 17189397
[TBL] [Abstract][Full Text] [Related]
38. [Glial tumors of the brain: current aspects of their classification and bases for genetic predisposition].
Anan'eva II; Malkarov MS; Korsakova NA; Balkanov AS; Dorofeev AE; Kachkov IA; Suchkov SV
Arkh Patol; 2007; 69(1):54-60. PubMed ID: 19385137
[TBL] [Abstract][Full Text] [Related]
39. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
40. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
